Advertisement

Topics

Reply to Farber, Chabra, and Kovesi.

08:00 EDT 11th October 2017 | BioPortfolio

Summary of "Reply to Farber, Chabra, and Kovesi."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: American journal of respiratory and critical care medicine
ISSN: 1535-4970
Pages:

Links

DeepDyve research library

PubMed Articles [1028 Associated PubMed Articles listed on BioPortfolio]

C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease.

Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceram...

Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1.

Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME), a rare disorder caused by mutation in the ASAH1 gene, is characterized by progressive muscle weakness and intractable epilepsy. T...

The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.

The use of intensive pediatric protocols for the treatment of ALL is being extended to older adults.

Response to Letter to the Editor: Author's Reply in Reply to: Ultrastructural Investigation of Pelvic Peritoneum in Patients with Chronic Pelvic Pain and Subtle Endometriosis in Association with Chromoendoscopy.

Factors to Consider for Reducing US Opioid-Related Deaths: Looking Beyond Access-Reply: Factors to Consider for Reducing US Opioid-Related Deaths-Reply.

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

FIND: Farber Disease Natural History Study

The primary objective of this study is to establish the natural history of Farber disease (acid ceramidase deficiency) through the collection and analysis of retrospective and prospective ...

Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication

The aim of this study is to assess the benefits from the AAISafeR/SafeR algorithm of Symphony 2550 or REPLY DR in a wide range of pacemaker patients. The expected benefits will be a resul...

Quality of Life in Colorectal (ex-)Cancer Patients, Based on the Belgian Cancer Registry.

This study is collecting data on quality of life, (care)needs and socio-economic factors in colorectal (ex-)cancer patients via a written questionnaire completed by the patient him/herself...

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

This study will add interleukin-2 (IL-2) to a regimen of post-remission therapy consisting of high-dose ara-C. Patients with AML in first remission will receive 3 cycles of high-dose ara-...

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

The purpose of this research study is to assess the safety and immune activity of a vaccine made from the participant's own cancer cells, when administered after a reduced intensity transp...

Medical and Biotech [MESH] Definitions

A sphingolipidosis subtype that is characterized by the histological appearance of granulomatous deposits in tissues. It results from the accumulation of CERAMIDES in various tissues due to an inherited deficiency of ACID CERAMIDASE.

A ceramidase subtype that is active at acid pH. It plays an important role in sphingolipid degradation by catalyzing the lysosomal hydrolysis of ceramide to sphingosine and free fatty acid. Inherited deficiency of acid ceramidase activity results in FARBER LIPOGRANULOMATOSIS.

Quick Search
Advertisement
 


DeepDyve research library

Searches Linking to this Article